figure26_large.png
PDF) The "dual-pathway" strategy after acute coronary syndrome: Rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial
ATLAS ACS2-TIMI 51 – TIMI STUDY GROUP
ATLAS ACS 2-TIMI 51: Primary Efficacy Endpoint CV Death / MI / Stroke - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
ATLAS - Rivaroxaban in patients with a recent ACS — NERDCAT
Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post‐Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS‐TIMI 46 and ATLAS ACS 2‐TIMI 51 | Journal of
Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial) - ScienceDirect
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial - The Lancet
ATLAS - Rivaroxaban in patients with a recent ACS — NERDCAT
60004-2.fp.png "RIVAROXABAN REDUCES SPONTANEOUS AND LARGE MYOCARDIAL INFARCTIONS: FINDINGS FROM THE ATLAS ACS 2 – TIMI 51 TRIAL | Journal of the American College of Cardiology")
RIVAROXABAN REDUCES SPONTANEOUS AND LARGE MYOCARDIAL INFARCTIONS: FINDINGS FROM THE ATLAS ACS 2 – TIMI 51 TRIAL | Journal of the American College of Cardiology
Factor Xa Inhibitors in Coronary Artery Disease - ppt download
Frontiers | Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis
Dia 1
Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction: Results From the ATLAS ACS-2–TIMI-51 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary
ATLAS ACS-TIMI 46 – TIMI STUDY GROUP
Dia 1
NOACS: Emerging data in ACS/IHD - ppt download
Unmet Needs in the Secondary Prevention in ACS: The Dual Pathway Approach (Transcript)
PPT - C. Michael Gibson, MS, MD on behalf of the ATLAS ACS 2 TIMI 51 Investigators PowerPoint Presentation - ID:1519803
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome | NEJM
ATLAS ACS 2-TIMI 51: Safety Endpoints - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
Results of the ATLAS ACS-TIMI 46 Study Published in The Lancet - wikidoc
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome | NEJM
ATLAS ACS 2-TIMI 51: Efficacy Endpoints: Very Low-Dose 2.5 mg BID - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
